Ianalumab + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Autoimmune Hemolytic Anemia (wAIHA)
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Trial Timeline
Dec 30, 2022 → Dec 19, 2028
NCT ID
NCT05648968About Ianalumab + Placebo
Ianalumab + Placebo is a phase 3 stage product being developed by Novartis for Warm Autoimmune Hemolytic Anemia (wAIHA). The current trial status is active. This product is registered under clinical trial identifier NCT05648968. Target conditions include Warm Autoimmune Hemolytic Anemia (wAIHA).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05624749 | Phase 3 | Active |
| NCT05639114 | Phase 3 | Active |
| NCT05648968 | Phase 3 | Active |
Competing Products
12 competing products in Warm Autoimmune Hemolytic Anemia (wAIHA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| Isatuximab SAR650984 | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly | Immunovant | Phase 2 | 49 |
| HMPL-523(300mg PO QD) + Placebo | HUTCHMED | Phase 2/3 | 60 |
| APL-2 | Apellis Pharmaceuticals | Phase 2 | 47 |
| Obexelimab + Obexelimab | Zenas BioPharma | Phase 3 | 72 |
| ANX005 | Annexon | Phase 2 | 47 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |
| Fostamatinib disodium + Placebo | Rigel Pharmaceuticals | Phase 3 | 69 |